Serum follicle-stimulating hormone levels predict time to development of castration resistant prostate cancer

Hoare, Dylan; Skinner, Tom; Black, Angela

doi:10.5489/cuaj.2545

Cited by 26 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fig 1 shows the procedure of literature search and study selection. The studies consisted of five RCTs [ 12 – 16 ], one prospective [ 19 ] and four retrospective cohort studies [ 17 , 18 , 20 , 21 ]. Basic characteristics, such as age, sex ratio, stone size and stone side, were described comparable between rigid URSL and PCNL group in each study and the data was presented in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Basic characteristics, such as age, sex ratio, stone size and stone side, were described comparable between rigid URSL and PCNL group in each study and the data was presented in Table 1 . Some studies also reported other basic characteristics that might make a difference in the clinical outcomes: preoperative renal function including serum creatinine (SCr), blood urea nitrogen (BUN) or golomeruar filtration rate (GFR), failed SWL history, and degree of hydronephrosis [ 14 , 15 , 17 , 19 , 20 ]. All the data was also comparable between the two groups according to each study.…”

Section: Resultsmentioning

confidence: 99%

“…As shown in Table 1 , all RCTs were rated Level 2 and cohort studies were rated Level 3.Fourcohort studies [ 17 – 20 ] scored ≥8 stars were considered to be of high quality while one study [ 21 ] was scored 7 stars. Fig 2A showed that all of the RCTs described suggested randomization.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Rigid ureteroscopic lithotripsy versus percutaneous nephrolithotomy for large proximal ureteral stones: A meta-analysis

Wang

Guo

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

ObjectTo compare the safety and efficacy of rigid ureteroscopic lithotripsy (rigid URSL) and percutaneous nephrolithotomy (PCNL) in treating large proximal ureteral stones.MethodsA systematic search of PubMed, EMBASE, Cochrane Library, and Web of Science databases was performed to find out relevant studies. After literature screening according to the predetermined inclusion and exclusion criteria, data of eligible studies was extracted and then a meta-analysis was conducted via RevMan 5.3 software.ResultsFive randomized controlled trials (RCTs), one prospective and four retrospective cohort studies involving 837 patients were included. Patients underwent rigid URSL were associated with shorter operation time (WMD, -23.66min; 95%CI, −45.00 to -2.32; p = 0.03), shorter hospital stay (WMD, -2.76d; 95%CI, −3.51 to −2.02; p< 0.00001), lower 3rd-day (RR, 0.73; 95%CI, 0.66 to 0.82; p < 0.00001) and 1st-month (RR, 0.82; 95%CI, 0.77 to 0.87; p < 0.00001) stone-free rate, higher risk of conversion to other surgical procedures (RR, 4.28; 95%CI, 1.93 to 9.46; p = 0.0003), higher incidence of migration (RR, 28.49; 95%CI, 9.12 to 89.00; p < 0.00001) and ureteral perforation (RR, 6.06; 95%CI, 1.80 to 20.44; p = 0.004), lower risk of fever (RR, 0.64; 95%CI, 0.42 to 0.97; p = 0.04), transfusion (RR, 0.19; 95%CI, 0.04 to 0.85; p = 0.03) and hematuria (RR, 0.38; 95%CI, 0.25 to 0.57; p < 0.0001). No significant difference was observed in terms of incidence of embolization, pain and ureterostenosis. When cohort studies or studies in which flexible ureteroscopy was used as an intraoperative auxiliary procedure were excluded, we both found that most of the results kept stable.ConclusionsBoth PCNL and rigid URSL are safe for patients with large proximal ureteral stones while PCNL is more effective in stone clearance.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Rigid ureteroscopic lithotripsy versus percutaneous nephrolithotomy for large proximal ureteral stones: A meta-analysis

Wang

Guo

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…24 Studies have shown correlations between serum FSH and the pathological stage of prostate cancer 23 and, more recently, time to castration resistant prostate cancer in a retrospective analysis. 25 …”

Section: Discussionmentioning

confidence: 99%

Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial

et al. 2017

View full text Add to dashboard Cite

Purpose Recent evidence suggests that reaching the lowest achievable levels of testosterone with androgen deprivation therapy delays disease progression and increases overall survival in men with advanced prostate cancer. The aim of this analysis is to compare the post-treatment serum testosterone levels between patients undergoing subcapsular orchiectomy and patients treated with the luteinizing hormone-releasing hormone agonist triptorelin. Material and Methods In this randomized clinical trial, we included 58 consecutive hormone-naive men diagnosed with advanced prostate cancer at Herlev and Gentofte University Hospital, Denmark, from September 2013 to March 2015. Follow-up was 48 weeks. Participants were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg given as 24 week depot injections. Androgen status was measured by liquid chromatography tandem mass spectrometry prior to treatment and after 12, 24 and 48 weeks. Between-group differences in achieved hormone levels were analyzed using longitudinal Tobit regressions. Results Triptorelin injections resulted in 29% (95% CI 17.2, 41.7) lower testosterone levels compared to subcapsular orchiectomy (p<.001). A significantly higher proportion of men receiving triptorelin had testosterone levels <20 ng/dL at 12 and 48 weeks compared to men undergoing orchiectomy (97% versus 79% and 100% versus 87%, p<.05). There was no detectable difference in adrenal androgen reductions between treatment groups. Conclusions The use of 24-week depot triptorelin injections results in significantly lower testosterone levels compared to subcapsular orchiectomy. This is the first randomized study to demonstrate a difference in treatment effect between surgical and medical castration on testosterone levels.

show abstract

“…In vitro studies detected overexpression of FSH receptors in prostate cancer compared to benign prostatic epithelium [ 60 ]. Moreover, a FSH value more than the lowest tertile (>4.8 mIU/mL) may be associated with shorter time to CRPC progression [ 61 ]. Taken together, the efficacy of GnRH antagonists may be due to lack of FSH stimulation as opposed to GnRH agonists.…”

Section: Introductionmentioning

confidence: 99%

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy

Pham

Sadowski

et al. 2015

Exp Hematol Oncol

View full text Add to dashboard Cite

Hormonal manipulation plays a significant role in the treatment of advanced hormone naïve prostate cancer and castration-resistant prostate cancer (CRPC) with or without previous chemotherapy. Combination of gonadotropin releasing hormone (GnRH) agonists and androgen receptor (AR) antagonists (combined androgen blockade; CAB) is the first line therapy for advanced hormone naïve prostate cancer, but current strategies are developing novel GnRH antagonists to overcome disadvantages associated with GnRH agonist monotherapy and CAB in the clinical setting. Abiraterone acetate and enzalutamide are hormonal agents currently available for patients with CRPC and are both shown to improve overall survival versus placebo. Recently, in clinical trials, testosterone has been administered in cycles with existing surgical and chemical androgen deprivation therapies (ADT) (intermittent therapy) to CRPC patients of different stages (low risk, metastatic) to abate symptoms of testosterone deficiency and reduce cost of treatment from current hormonal therapies for patients with CRPC. This review will provide an overview on the therapeutic roles of hormonal manipulation in advanced hormone naïve and castration-resistant prostate cancers, as well as the development of novel hormonal therapies currently in preclinical and clinical trials.

show abstract

Serum follicle-stimulating hormone levels predict time to development of castration resistant prostate cancer

Cited by 26 publications

References 27 publications

Rigid ureteroscopic lithotripsy versus percutaneous nephrolithotomy for large proximal ureteral stones: A meta-analysis

Rigid ureteroscopic lithotripsy versus percutaneous nephrolithotomy for large proximal ureteral stones: A meta-analysis

Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy

Contact Info

Product

Resources

About